China's Health Reform Will Nurture New Drugs, While Boosting Use Of Old Ones - PharmAsia Summit
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - In addition to dramatically increasing access to mainly generic drugs, China's sweeping and upcoming health reform will also include measures designed to spur R&D, according to Song Ruilin, Executive Director-General at the Chinese Pharmaceutical Association's Research Center for Medicinal Policy
You may also be interested in...
China's Commitment To Healthcare Coverage Late In Coming
HONG KONG - Any of the shiny new shopping malls in Shanghai provides an ideal place to observe the worsening dietary habits of China's new urban class
China's Commitment To Healthcare Coverage Late In Coming
HONG KONG - Any of the shiny new shopping malls in Shanghai provides an ideal place to observe the worsening dietary habits of China's new urban class
China Needs To Balance Equal Access To Affordable Medicines With Sharpening Focus On Innovative Drugs In Mapping Out Future, Say Leaders At DIA Conference
BEIJING - As China launches sweeping health system reforms in phases over the next decade, the country must balance competing interests in mapping out the future: laying the groundwork for affordable and ultimately universal coverage while promoting the development of research- and capital-intensive innovative medicines, according to drug industry, academic and policy-making leaders who provided glimpses of the road ahead during the second annual meeting of the Drug Information Association in China